Jaguar Animal Health (NASDAQ:JAGX – Get Free Report) and Telomir Pharmaceuticals (NASDAQ:TELO – Get Free Report) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their profitability, valuation, institutional ownership, risk, dividends, earnings and analyst recommendations.
Analyst Ratings
This is a summary of current ratings and recommmendations for Jaguar Animal Health and Telomir Pharmaceuticals, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Jaguar Animal Health | 1 | 0 | 1 | 0 | 2.00 |
| Telomir Pharmaceuticals | 1 | 1 | 1 | 0 | 2.00 |
Jaguar Animal Health presently has a consensus price target of $60.00, indicating a potential upside of 14,552.01%. Given Jaguar Animal Health’s higher possible upside, analysts clearly believe Jaguar Animal Health is more favorable than Telomir Pharmaceuticals.
Insider and Institutional Ownership
Risk and Volatility
Jaguar Animal Health has a beta of 0.27, suggesting that its share price is 73% less volatile than the S&P 500. Comparatively, Telomir Pharmaceuticals has a beta of -0.73, suggesting that its share price is 173% less volatile than the S&P 500.
Earnings and Valuation
This table compares Jaguar Animal Health and Telomir Pharmaceuticals”s gross revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Jaguar Animal Health | $11.51 million | 0.13 | -$38.49 million | ($33.24) | -0.01 |
| Telomir Pharmaceuticals | N/A | N/A | -$10.41 million | ($0.33) | -4.00 |
Telomir Pharmaceuticals has lower revenue, but higher earnings than Jaguar Animal Health. Telomir Pharmaceuticals is trading at a lower price-to-earnings ratio than Jaguar Animal Health, indicating that it is currently the more affordable of the two stocks.
Profitability
This table compares Jaguar Animal Health and Telomir Pharmaceuticals’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Jaguar Animal Health | -341.90% | -1,194.94% | -80.16% |
| Telomir Pharmaceuticals | N/A | -315.26% | -259.29% |
Summary
Jaguar Animal Health beats Telomir Pharmaceuticals on 7 of the 11 factors compared between the two stocks.
About Jaguar Animal Health
Jaguar Health, Inc., a commercial stage pharmaceuticals company, focuses on developing plant-based prescription medicines for people and animals with gastrointestinal distress, specifically chronic and debilitating diarrhea. The company operates through two segments, Human Health and Animal Health. It focuses on developing and commercializing prescription and non-prescription products for companion and production animals; and human products. The company's products include Mytesi, an anti-secretory antidiarrheal drug for the symptomatic relief of non-infectious diarrhea in adults with HIV/AIDS on antiretroviral therapy; and Canalevia-CA1, a prescription drug product for chemotherapy-induced diarrhea in dogs. It is also developing Crofelemer, an anti-secretory antidiarrheal drug, which is in Phase 3 clinical trial for or prophylaxis of diarrhea in adult cancer patients, and to address rare/orphan disease indications, including short bowel syndrome with intestinal failure and/or congenital diarrheal disorders; diarrhea-predominant irritable bowel syndrome; and for idiopathic/functional diarrhea. In addition, the company is developing NP-300, a second-generation antidiarrheal drug for symptomatic relief and treatment of moderate-to-severe diarrhea. The company is headquartered in San Francisco, California.
About Telomir Pharmaceuticals
Telomir Pharmaceuticals, Inc., a pre-clinical-stage pharmaceutical company, focuses on the development and commercialization of therapeutic treatment for human stem cells. The company develops TELOMIR-1, a novel small molecule being developed to function as an oral in situ therapeutic intervention against age-related inflammatory conditions, such as hemochromatosis and osteoarthritis, as well as for post-chemotherapy health problems. The company was formerly known as Metallo Therapies Inc. and changed its name to Telomir Pharmaceuticals, Inc. in October 2022. Telomir Pharmaceuticals, Inc. was incorporated in 2021 and is headquartered in Baltimore, Maryland.
Receive News & Ratings for Jaguar Animal Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jaguar Animal Health and related companies with MarketBeat.com's FREE daily email newsletter.
